Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered T-Cells take on recurrent solid tumors in new trial

NCT ID NCT03686124

Recruiting now Disease control Sponsor: Immatics US, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cells. Some participants will also receive the drug nivolumab (Opdivo) to boost the immune response. The trial aims to find the safest dose and see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Genetically modified immune cells (T-cells) designed to target PRAME protein, sometimes combined with nivolumab (Opdivo)

What this could lead to

If successful, this could offer a new treatment option for people with hard-to-treat solid tumors that have stopped responding to standard therapies.

What could go wrong

This is an early-phase trial (Phase 1/2) with a small number of participants, so the treatment may not work for many people. There are also risks of serious side effects from the cell therapy and the combination with nivolumab.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer endometrial carcinoma fallopian tube cancer melanoma neoplasm ovarian cancer Recurrence refractory malignant neoplasm Uveal Melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER RECURRENT CANCER REFRACTORY CANCER SOLID TUMOR, ADULT

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie

    RECRUITING

    Berlin, 12203, Germany

  • Fox Chase Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19111, United States

    Contact

    Contact Email: •••••@•••••

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Email: •••••@•••••

  • Klinikum rechts der Isar der Technischen Universität München

    RECRUITING

    Munich, Bavaria, 81675, Germany

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run

    RECRUITING

    Columbus, Ohio, 43026, United States

    Contact Email: •••••@•••••

  • Stanford Cancer Institute

    RECRUITING

    Stanford, California, 94305, United States

    Contact Email: •••••@•••••

  • Thomas Jefferson University, Honickman Center

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Chicago Medical Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact

  • University of Colorado, Anschutz Medical Campus

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-••••

  • University of Miami Hospital and Clinics

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pennsylvania, Perelamn Center for Advanced Medicine

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Email: •••••@•••••

  • University of Pittsburgh Medical Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Universitätsklinikum Bonn - Medizinische Klinik III

    RECRUITING

    Bonn, North Rhine-Westphalia, 53127, Germany

  • Universitätsklinikum C.-G.-Carus Dresden

    RECRUITING

    Dresden, Saxony, 01307, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    RECRUITING

    Hamburg, 20246, Germany

  • Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)

    RECRUITING

    Heidelberg, Baden-Wurttemberg, 69120, Germany

  • Universitätsklinikum Würzburg

    RECRUITING

    Würzburg, Bavaria, 97080, Germany

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    RECRUITING

    Mainz, Rhineland-Palatinate, 55131, Germany